Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on September 28, 2026.

Title: Addex Therapeutics Reports 2026 Half-Year and Second Quarter Financial Results and Provides Corporate Update Date: September 28, 2026 Time: 16:00 CET (15:00 BST / 10:00 EDT / 07:00 PDT)